Study comparing siplizumab to another drug for kidney transplant acceptance
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting a kidney transplant from a living or deceased donor that is not a perfect tissue match.
- The donor kidney must have been stored for less than 30 hours before transplant.
- If you are able to become pregnant, you must agree to use highly effective birth control.
- You must not have had a positive test for donor-specific antibodies before transplant.
- You cannot have had a previous kidney transplant or a transplant of another organ.
- You must not be taking certain immune-suppressing drugs or have certain infections like HIV or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
This study tests whether giving a special mix of donor immune cells along with immune-suppressing medicines right after a kidney transplant can help the body accept the new kidney without long-term anti-rejection drugs. It aims to reduce the need for daily transplant medications.
This trial tests a blood test that may help monitor kidney transplant health by detecting signs of rejection earlier. It aims to see if using this blood test can lead to better long-term outcomes for transplant recipients.
This trial tests if adding silymarin (a milk thistle extract) to standard anti-rejection medicines helps protect the new kidney from damage. It may improve how well the transplanted kidney works over time.
Hear when a new Renal Transplant Failure and Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.